Pharmaron Beijing Co., Ltd. (HKG:3759)

Market Cap	43.03B
Revenue (ttm)	13.62B
Net Income (ttm)	2.00B
Shares Out	n/a
EPS (ttm)	1.13
PE Ratio	21.48
Forward PE	20.98
Dividend	0.22 (1.37%)
Ex-Dividend Date	Jun 27, 2024

Volume	6,899,001
Average Volume	10,190,912
Open	15.74
Previous Close	15.58
Day's Range	15.48 - 16.26
52-Week Range	7.98 - 24.85
Beta	0.91
RSI	53.76
Earnings Date	Aug 7, 2025

About Pharmaron Beijing

Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, and internationally. The company offers laboratory chemistry services, including medicinal and synthetic chemistry, chemistry for new modalities, radiolabelling and radiosynthesis, analytical and purification chemistry, DNA-encoded libraries, cheminformatics, and computer-aided drug design; bioscience services, such as structural biology, in vi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 21,370
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3759

Financial Performance

In 2024, Pharmaron Beijing's revenue was 12.28 billion, an increase of 6.39% compared to the previous year's 11.54 billion. Earnings were 1.79 billion, an increase of 12.01%.

Financial numbers in CNY